ALC Alcon Inc.

Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference

GENEVA--(BUSINESS WIRE)--

Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST.

A live webcast of the conference will be available at .

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at .

Connect with us on



EN
31/12/2024

Underlying

ALCAlcon Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alcon Inc.

Jean Danjou
  • Jean Danjou
ADP AEROPORTS DE PARIS SA
DB1 DEUTSCHE BOERSE AG
PUM PUMA SE
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
AFX CARL ZEISS MEDITEC AG
FHZN FLUGHAFEN ZURICH AG
VIRP VIRBAC SA
VETO VETOQUINOL SA
EOAN E.ON SE
BC BRUNELLO CUCINELLI S.P.A.
ALC ALCON INC.
11h / 4m 11h / 4m 1 EN
Jean Danjou
  • Jean Danjou
ADP AEROPORTS DE PARIS SA
DB1 DEUTSCHE BOERSE AG
PUM PUMA SE
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
AFX CARL ZEISS MEDITEC AG
FHZN FLUGHAFEN ZURICH AG
VIRP VIRBAC SA
VETO VETOQUINOL SA
EOAN E.ON SE
BC BRUNELLO CUCINELLI S.P.A.
ALC ALCON INC.
11h / 16m 11h / 16m 1 FR
Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf
ALC ALCON INC.

Alcon AG : Sharpening vision in a structurally growing market

Alcon is a world leading pure-play eye care company, operating in two highly attractive and structurally growing markets: Ophthalmic Surgery and Vision Care. Supported by several structural growth drivers, these markets are expected to experience steady mid-single-digit growth. Alcon is projected to outperform this, driven by market share gains through product innovation. It enjoys high revenue recurrence (around 90%), a 2024-30e core EPS CAGR of 10.4%, strong free cash flow, and thus a solid ba...

12/10/25 December 10, 2025 1 EN
 PRESS RELEASE
Free
ALC ALCON INC.

Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond...

March 24, 2025 1 EN
 PRESS RELEASE
Free
ALC ALCON INC.

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: . Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care product...

March 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch